Plandai Biotechnology reached an agreement in principal with North West University, to begin human clinical trials on the island of Mauritius, a member of the SADC group of African countries, to determine the effectiveness of using Phytofare catechin complex in regulating insulin levels in Type II Diabetes patients. According to a media release, North West University and the Company are finalizing the trial protocols which has a provisional start date of November 2016. Mauritius was selected as the trial site because, according to the World Health Organization and the International Diabetes Federation (IDF), the prevalence of Type II Diabetes in Mauritius in 2015 was 16.28%. The company said that the proposed double-blind study will encompass 100 patients over 3 months, with a cross-over to the alternative treatment after 3 months, resulting in a total trial duration of 6 months. Compared to generic green tea extracts, Plandai's Phytofare Catechin Complex has been clinically shown to deliver ten times greater levels of catechins to the blood plasma where they remain at therapeutic levels for over 24 hours.